Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 25, 2004
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (Dental, Medical, and International) and Technology (software and value-added services).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 25, 2004 |
Three Months Ended Sep 27, 2003 |
Nine Months Ended Sep 25, 2004 |
Nine Months Ended Sep 27, 2003 |
|---|---|---|---|---|
| Net Sales | $1,033,625 | $892,718 | $2,865,946 | $2,406,881 |
| Gross Profit | $274,028 | $251,500 | $756,570 | $673,446 |
| Gross Margin % | 26.5% | 28.2% | 26.4% | 28.0% |
| Operating Income | $53,155 | $76,400 | $163,040 | $174,635 |
| Net Income | $31,504 | $44,347 | $98,633 | $101,968 |
| Diluted EPS | $0.71 | $0.99 | $2.20 | $2.27 |
| Cash from Operations (9mo) | $57,579 (2004) vs $18,091 (2003) | |||
| Total Debt | $533,487 (Sep 25, 2004) vs $256,412 (Dec 27, 2003) | |||
| Working Capital | $730,196 (Sep 25, 2004) vs $637,296 (Dec 27, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.8% for the quarter and 19.1% for the nine-month period. Growth was driven by acquisitions (notably the Demedis Group in Europe) and internal growth in dental consumables and equipment.
- Profitability Decline: Operating income decreased 30.4% for the quarter and 6.6% for the nine-month period. Net income dropped 29.0% for the quarter and 3.3% for the nine-month period.
- Margin Compression: Gross margins declined from 28.2% to 26.5% (quarter) and 28.0% to 26.4% (nine months). This was primarily due to the absence of high-margin Fluvirin influenza vaccine sales and a shift toward lower-margin vaccines and injectables.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 26.1% for the quarter, largely due to payroll increases associated with recent acquisitions.
- Balance Sheet: Long-term debt increased significantly to $522.8 million (from $247.1 million) following the issuance of $240 million in convertible notes to finance acquisitions. Cash and cash equivalents decreased to $73.0 million from $157.4 million.
Guidance, Outlook, and Risks
- Revised Guidance: In October 2004, the company revised its full-year 2004 diluted EPS guidance downward to $3.03–$3.07 (previously $3.55–$3.61).
- Fluvirin Shortage: The revision was caused by Chiron Corporation's suspension of Fluvirin influenza vaccine production due to UK regulatory action. Henry Schein is the primary U.S. distributor. The company expects a one-time pre-tax charge of approximately $13 million related to deferred expenses if the vaccine is unavailable for the 2005/2006 season.
- Acquisitions: The company completed the acquisition of the Demedis Group (Germany, Italy, Benelux) and Camlog (Switzerland). Regulatory approval is still pending for the Austrian operations (Austrodent).
- Capital Allocation: The company authorized a new $100 million stock repurchase program in June 2004, having repurchased $28.3 million of shares by the end of the quarter.
- Risks: Key risks include supply chain disruptions (specifically influenza vaccines), integration challenges of recent acquisitions, foreign currency fluctuations, and intense competition in the healthcare distribution sector.
Investor Verification Checklist
- Fluvirin Impact: Verify the status of the Chiron vaccine suspension and the potential timing of the $13 million charge.
- Acquisition Integration: Assess the progress of integrating the Demedis Group and the regulatory outcome for the Austrodent acquisition.
- Debt Structure: Review the terms of the new $240 million convertible debt (3.0% interest, due 2034) and its impact on future interest expenses and potential dilution.
- Margin Recovery: Monitor whether gross margins can recover as the company adjusts to the absence of high-margin vaccine sales.
- Legal Proceedings: Track the status of the Texas class action regarding practice management software and the New Jersey influenza vaccine class action.